Kandesar (Candesartan Cilexetil)

Kandesar belongs to the Angiotensin II receptor blocker class and is employed in cardiovascular and renal disease management.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure: improves symptoms and reduces hospitalisation by decreasing cardiac afterload.
• Diabetic nephropathy: slows progression of kidney damage by lowering intraglomerular pressure.

• Candesartan cilexetil is a prodrug that is converted to candesartan, a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1 receptors, it prevents angiotensin II‑mediated vasoconstriction, aldosterone secretion, and sodium retention, leading to vasodilation, reduced blood volume, and ultimately lower arterial pressure.

Kandesar may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness, especially after the first dose.
• Headache.
• Fatigue or general weakness.
• Upper respiratory tract infection symptoms.
• Nasal congestion or sinus discomfort.

Serious or Rare Side Effects

• Angioedema involving the face, lips, tongue or throat.
• Significant hypotension leading to fainting.
• Acute kidney injury or worsening renal function.
• Hyperkalemia (elevated blood potassium).
• Elevated liver enzymes indicating hepatic stress.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Blood pressure monitoring: ensure adequate control and avoid excessive hypotension.
• Renal function assessment: check serum creatinine and eGFR periodically.
• Electrolyte surveillance: monitor potassium levels, especially with concomitant potassium‑sparing agents.
• Hepatic impairment: use with caution in patients with moderate to severe liver disease.
• Pregnancy: avoid use during pregnancy due to potential fetal toxicity.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Kandesar can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment.
• Combination with potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• Co‑administration with ACE inhibitors: heightened risk of hypotension, hyperkalemia, and renal dysfunction.

Moderate Interactions (Monitor Closely)

• NSAIDs: may attenuate antihypertensive effect and impair renal function.
• Lithium: candesartan can raise lithium levels, requiring serum monitoring.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase candesartan exposure.
• Other antihypertensives: additive blood pressure‑lowering effect, necessitating dose adjustments.